Results 111 to 120 of about 18,181 (226)
Recommendations on biosimilar low-molecular-weight heparins.
International audienceBased on the results of large clinical trials, several low-molecular-weight heparins (LMWHs) have been approved for prophylaxis and the treatment of venous and arterial thromboembolism.
Harenberg, J. +35 more
core +1 more source
In this meta‐analysis of eight studies (508 children with inflammatory bowel disease), switching from originator to biosimilar infliximab preserved clinical remission, drug exposure, and immunogenicity, with high treatment persistence and no signal of efficacy or safety loss. Biosimilar switching appears a safe, effective option in pediatric IBD.
Douglas Amaral da Silva Menegazzo Miotto +4 more
wiley +1 more source
Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality.
Biogen
core
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah +9 more
wiley +1 more source
Characteristics of trials comparing biosimilar and reference insulins.
Characteristics of trials comparing biosimilar and reference insulins.
Carolyn Tieu (5117252) +4 more
core +1 more source
G.-R. Burmester, U. Müller-Ladner
openaire +4 more sources
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco +13 more
wiley +1 more source
FDA Approves Trastuzumab Biosimilar
On December 1, the FDA approved a second cancer biosimilar, trastuzumab-dkst. The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers.
core +1 more source
OBJECTIVES: The clinical efficacy of biologic/targeted synthetic/biosimilar disease modifying antirheumatic drugs (b/ts/biosimilar DMARDs) in treating inflammatory arthritis is well documented, while the economic performance of these agents remains vague.
Peng, K +6 more
core

